Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · APLLTD

ALEM PHARMA

HealthcarePharmaceuticals & Biotechnology₹20512 cr market cap
₹1049.60 ▲ +0.5% today As of 19 Nov 2026
52-week low ₹646.5552-week high ₹1057.10

-1.2% from the 52-week high · +61.5% above the low

Alembic Pharmaceuticals Ltd. is a research and development pharmaceutical company, which engages in the research, development, manufacture, and market of generic and branded pharmaceutical products. The company is headquartered in Vadodara, Gujarat and currently employs 14,593 full-time employees. The company went IPO on 2011-09-17. The firm is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). The company delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. The company has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.

The short version. ALEM PHARMA reported revenue of ₹2,603 crore for Sep 2026, up 36.3% from a year earlier. Net profit was ₹335 crore (up 81.1% year on year). Return on equity was 11.9% in Mar 2026. Promoter holding was 69.87% in Sep 2026, up 0.26 points over 8 quarters.

1 · The price

How has the stock traded?

ALEM PHARMA trades 1.2% below its 52-week high and 61.5% above its 52-week low.

Change over period: —

1M+32.1%
3M+27.7%
6M+38.8%
1Y+14.3%

2 · The business

Is it growing?

Sales, year on year+36.3%

Sep 2026 revenue of ₹2,603 cr.

Profit, year on year+81.1%

Sep 2026 net profit of ₹335 cr.

Net margin12.9%

3.2 pts higher than a year earlier.

3-year growth25.4% profit

Revenue compounded at 9.4% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue26032150184818761910171117701693
Net profit335173203133185154157138
Net margin %12.98.111.07.19.79.08.98.2
EPS (₹)17.058.810.316.769.47.857.987.04

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue73456672622956535306539346063935
Net profit6755836163425461178829-1
Net margin %9.28.79.96.110.321.818.0-0.0
EPS (₹)34.3329.6831.3317.427.7659.9443.97-0.06

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.9% in Mar 2026; debt to equity is 0.24.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.911.212.87.8
Return on capital %12.814.613.89.6
EBITDA margin %14.915.815.412.6
Net margin %9.18.79.86.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR9.4%6.5%
Profit CAGR25.4%-10.5%
Debt to equity0.24
Interest cover8.4x
Current ratio1.75
P/E ratio24.5

4 · The owners

Who holds it, and are they adding?

Promoter holding69.87%

Up 0.26 pts over 8 quarters.

Foreign institutions4.55%

Up 0.38 pts over 8 quarters.

Domestic institutions15.43%

Down 0.63 pts over 8 quarters.

Mutual fund schemes32

+2 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter69.6169.6769.6769.7469.7469.7469.8769.87+0.26
FII4.173.943.964.054.244.254.184.55+0.38
DII16.0616.4316.4616.316.1716.1815.9415.43-0.63
Public10.169.969.99.929.859.8310.0110.15-0.01

Mutual fund holdings · Oct 2026

32 schemes hold this stock

30 the month before.

  • DSP Healthcare Fund3.09% of NAV
  • ICICI Prudential Healthcare Fund2.33% of NAV
  • UTI - Healthcare Fund1.78% of NAV
  • The Wealth Company Mid cap fund1.65% of NAV
  • Kotak Small Cap Fund1.53% of NAV
  • Abakkus Small Cap Fund1.51% of NAV
  • THE WEALTH COMPANY FLEXI CAP FUND1.44% of NAV
  • UTI - MNC Fund1.25% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ALEM PHARMA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ALEM PHARMA

What is the ALEM PHARMA share price?

ALEM PHARMA (APLLTD) last closed at ₹1,049.60, up 0.5% on the day. Its 52-week range is ₹646.55 to ₹1,057.10.

What is the market cap of ALEM PHARMA?

ALEM PHARMA has a market capitalisation of about ₹20,512 crore. Its price-to-earnings ratio is 24.5.

How are ALEM PHARMA's latest results?

ALEM PHARMA reported revenue of ₹2,603 crore for Sep 2026, up 36.3% from a year earlier. Net profit was ₹335 crore (up 81.1% year on year). Return on equity was 11.9% in Mar 2026. Promoter holding was 69.87% in Sep 2026, up 0.26 points over 8 quarters.

Who owns ALEM PHARMA?

As of Sep 2026, shareholding was: Promoter 69.87%, FII 4.55%, DII 15.43%, Public 10.15%.

How many mutual funds hold ALEM PHARMA?

32 mutual fund schemes held ALEM PHARMA in October 2026. That compares with 30 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 29 Jul 2025 · Final Dividend - Rs. 11
  • 15 Jul 2024 · Final Dividend - Rs. 11
  • 28 Jul 2023 · Final Dividend - Rs. 8
  • 17 Aug 2022 · Interim Dividend - Rs. 10
  • 19 Jul 2021 · Dividend - Rs. 14
  • 16 Mar 2020 · Interim Dividend - Rs. 7

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.